6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Discovery of Small-Molecule Nonfluorescent Inhibitors of Fluorogen-Fluorogen Activating Protein Binding Pair.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A new class of biosensors, fluorogen activating proteins (FAPs), has been successfully used to track receptor trafficking in live cells. Unlike the traditional fluorescent proteins (FPs), FAPs do not fluoresce unless bound to their specific small-molecule fluorogens, and thus FAP-based assays are highly sensitive. Application of the FAP-based assay for protein trafficking in high-throughput flow cytometry resulted in the discovery of a new class of compounds that interferes with the binding between fluorogens and FAP, thus blocking the fluorescence signal. These compounds are high-affinity, nonfluorescent analogs of fluorogens with little or no toxicity to the tested cells and no apparent interference with the normal function of FAP-tagged receptors. The most potent compound among these, N,4-dimethyl-N-(2-oxo-2-(4-(pyridin-2-yl)piperazin-1-yl)ethyl)benzenesulfonamide (ML342), has been investigated in detail. X-ray crystallographic analysis revealed that ML342 competes with the fluorogen, sulfonated thiazole orange coupled to diethylene glycol diamine (TO1-2p), for the same binding site on a FAP, AM2.2. Kinetic analysis shows that the FAP-fluorogen interaction is more complex than a homogeneous one-site binding process, with multiple conformational states of the fluorogen and/or the FAP, and possible dimerization of the FAP moiety involved in the process.

          Related collections

          Author and article information

          Journal
          J Biomol Screen
          Journal of biomolecular screening
          SAGE Publications
          1552-454X
          1087-0571
          Jan 2016
          : 21
          : 1
          Affiliations
          [1 ] Department of Pathology, University of New Mexico, Albuquerque, NM, USA Center for Molecular Discovery, University of New Mexico, Albuquerque, NM, USA.
          [2 ] Vanderbilt Specialized Chemistry Center, Vanderbilt University Medical Center, Nashville, TN, USA.
          [3 ] Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
          [4 ] Center for Molecular Discovery, University of New Mexico, Albuquerque, NM, USA.
          [5 ] Molecular Biosensor and Imaging Center, Carnegie Mellon University, Pittsburgh, PA, USA.
          [6 ] Molecular Biosensor and Imaging Center, Carnegie Mellon University, Pittsburgh, PA, USA Department of Biological Science, Carnegie Mellon University, Pittsburgh, PA, USA.
          [7 ] Department of Pathology, University of New Mexico, Albuquerque, NM, USA Center for Molecular Discovery, University of New Mexico, Albuquerque, NM, USA Lsklar@salud.unm.edu.
          Article
          1087057115609145
          10.1177/1087057115609145
          26442911
          1aed2d93-4fa9-4661-9c36-44847af62a6a
          History

          drug discovery,biosensor,protein trafficking,crystal structure,fluorogen activating protein

          Comments

          Comment on this article